Gil Yosipovitch, Marjolein de Bruin-Weller, Marni Wiseman, Jesper Elberling, Jan Gutermuth, Evangeline Pierce, Sonia Montmayeur, Fan Emily Yang, Yuxin Ding, Laia Bardolet, Sarah Chisolm
{"title":"lebrikizumab单药治疗患者的生活质量改善是通过改善瘙痒和睡眠来调节的：来自中重度特应性皮炎患者的两项3期试验的结果。","authors":"Gil Yosipovitch, Marjolein de Bruin-Weller, Marni Wiseman, Jesper Elberling, Jan Gutermuth, Evangeline Pierce, Sonia Montmayeur, Fan Emily Yang, Yuxin Ding, Laia Bardolet, Sarah Chisolm","doi":"10.1093/ced/llae541","DOIUrl":null,"url":null,"abstract":"<p><p>Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody that binds interleukin-13, a key cytokine implicated in AD. This study includes data from two phase III randomized controlled trials that assessed the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post hoc analysis to quantify the effect of lebrikizumab vs. placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes, specifically itch and the interference of itch on sleep. Approximately two-thirds of the improvement at week 16 in DLQI experienced by patients treated with lebrikizumab vs. patients treated with placebo was mediated by improvements in itch and the interference of itch on sleep.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1188-1192"},"PeriodicalIF":3.7000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis.\",\"authors\":\"Gil Yosipovitch, Marjolein de Bruin-Weller, Marni Wiseman, Jesper Elberling, Jan Gutermuth, Evangeline Pierce, Sonia Montmayeur, Fan Emily Yang, Yuxin Ding, Laia Bardolet, Sarah Chisolm\",\"doi\":\"10.1093/ced/llae541\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody that binds interleukin-13, a key cytokine implicated in AD. This study includes data from two phase III randomized controlled trials that assessed the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post hoc analysis to quantify the effect of lebrikizumab vs. placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes, specifically itch and the interference of itch on sleep. Approximately two-thirds of the improvement at week 16 in DLQI experienced by patients treated with lebrikizumab vs. patients treated with placebo was mediated by improvements in itch and the interference of itch on sleep.</p>\",\"PeriodicalId\":10324,\"journal\":{\"name\":\"Clinical and Experimental Dermatology\",\"volume\":\" \",\"pages\":\"1188-1192\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ced/llae541\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llae541","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis.
Pruritus is a hallmark symptom of atopic dermatitis (AD) and is known to worsen patients' health-related quality of life. Lebrikizumab is a high-affinity monoclonal antibody that binds interleukin-13, a key cytokine implicated in AD. This study includes data from two phase III randomized controlled trials that assessed the efficacy and safety of lebrikizumab in patients with moderate-to-severe AD, ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). We report a post hoc analysis to quantify the effect of lebrikizumab vs. placebo on the Dermatology Life Quality Index (DLQI) mediated indirectly through its effect on patient-reported outcomes, specifically itch and the interference of itch on sleep. Approximately two-thirds of the improvement at week 16 in DLQI experienced by patients treated with lebrikizumab vs. patients treated with placebo was mediated by improvements in itch and the interference of itch on sleep.
期刊介绍：
Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
